Leuzzi V, Bianchi M C, Tosetti M, Carducci C L, Carducci C A, Antonozzi I
Dipartimento di Scienze Neurologiche e Psichiatriche dell'Età Evolutiva, Università La Sapienza, Rome, Italy.
J Inherit Metab Dis. 2000 Sep;23(6):563-70. doi: 10.1023/a:1005621727560.
Recent studies using in vivo proton magnetic resonance spectroscopy (1H MRS) have suggested that plasma phenylalanine (Phe) may not be a reliable indicator of brain Phe level in subjects with phenylketonuria (PKU). Interindividual variation in cerebral Phe can contribute to the phenotypic variability of the disease. We report the results of the direct assessment of brain Phe by 1H MRS in 10 off-diet PKU patients (aged 15.5-30.5 years), 4 detected and treated early, 6 late. In a single patient, brain Phe was evaluated before and 15 days after diet discontinuation. FLAIR MRI and 1H MRS were performed in the same setting by a 1.5 T clinical MR scanner. MR images were scored according to the extent of the lobar white-matter hyperintensity. Brain 1H MRS Phe signal (resonating at 7.36 ppm) was evaluated as a ratio to the creatine+phosphocreatine signal. Brain Phe was correlated with clinical, biochemical and MRI findings. Results were as follows. (1) An abnormal concentration of brain Phe was detected in all 10 PKU subjects (ranging from 0.030 to 0.074), associated with a wide interindividual variability of concurrent plasma Phe (ranging from 724 to 2800 micromol/L). (2) In late-detected subjects, brain Phe concentration correlated with clinical phenotype better than did plasma Phe. The discrepancy between brain and plasma Phe was relevant from a clinical point of view in two cases: in one, a late-detected patient with normal mental development, a high level of plasma Phe was associated with a relatively low concentration of brain Phe; in the other, a late-detected subject with severe neurological impairment, a very high level of brain Phe was associated with plasma Phe compatible with the diagnosis of mild PKU. (3) White-matter alterations were detected in all patients. FLAIR MRI sequences disclosed an involvement of optic chiasma and tracts in 7 subjects. No correlation was found between white-matter alterations and concurrent brain Phe concentrations. (4) In the only case assessed under different intake of Phe, the relevant increase of brain Phe paralleled the concurrent increase of plasma Phe, showing that 1H MRS can be a useful tool in evaluating the individual vulnerability of PKU patients to different values of plasma Phe.
近期使用体内质子磁共振波谱法(1H MRS)的研究表明,对于苯丙酮尿症(PKU)患者,血浆苯丙氨酸(Phe)可能并非脑内Phe水平的可靠指标。脑内Phe的个体差异可能导致该疾病表型的变异性。我们报告了10名已停止饮食治疗的PKU患者(年龄在15.5 - 30.5岁之间)通过1H MRS直接评估脑内Phe的结果,其中4例为早期发现并接受治疗,6例为晚期发现。在一名患者中,于停止饮食前及停止饮食15天后评估脑内Phe。通过1.5T临床磁共振扫描仪在相同条件下进行液体衰减反转恢复序列(FLAIR)磁共振成像和1H MRS检查。根据脑叶白质高信号的范围对磁共振图像进行评分。将脑内1H MRS的Phe信号(共振于7.36 ppm)评估为与肌酸 + 磷酸肌酸信号的比值。将脑内Phe与临床、生化及磁共振成像结果进行相关性分析。结果如下:(1)在所有10名PKU受试者中均检测到脑内Phe浓度异常(范围为0.030至0.074),同时血浆Phe存在较大的个体间变异性(范围为724至2800 μmol/L)。(2)在晚期发现的受试者中,脑内Phe浓度与临床表型的相关性优于血浆Phe。从临床角度来看,脑内和血浆Phe之间的差异在两例中较为显著:一例为晚期发现且智力发育正常的患者,血浆Phe水平高但脑内Phe浓度相对较低;另一例为晚期发现且有严重神经功能障碍的受试者,脑内Phe水平极高而血浆Phe水平与轻度PKU诊断相符。(3)在所有患者中均检测到白质改变。FLAIR磁共振成像序列显示7名受试者的视交叉和视束受累。未发现白质改变与同期脑内Phe浓度之间存在相关性。(4)在唯一一例在不同Phe摄入量下进行评估的病例中,脑内Phe的相应增加与血浆Phe的同期增加平行,表明1H MRS可作为评估PKU患者对不同血浆Phe值个体易感性的有用工具。